Southern Alberta Myeloma Patient Society

Advocacy

 

Advocacy

We are very pleased to announce that the tutorial on How cancer drug funding decisions are made is now available for download from www.pcodr.ca andwww.cancerview.ca/cancerdrugfunding. 
 
The tutorial on How cancer drug funding decisions are made is the result of a joint collaboration between the pan-Canadian Oncology Drug Review ("pCODR") and the Canadian Partnership Against Cancer ("the Partnership"). The tutorial was developed with input from patient representatives, patient advocates, clinicians and decision-makers. 
 
This tutorial explains the process that decision makers in Canada follow to decide whether to publicly fund new cancer drugs. It is intended to provide information on which groups are involved in this process, how new drugs are evaluated, how health benefits, costs and values play into the decision, and how an individual could participate in cancer drug decision-making panels. This tutorial describes drug funding decision making in Canada as it is currently best practiced. The tutorial describes decision making for Canadians as a whole and does not help individuals decide which therapies are right for them.    
 
Cancer drug funding decisions are tougher than ever because of trends like the increasing use of cancer therapies and the rapid introduction of new high-cost cancer drugs which may have limited benefits. In this context, there needs to be processes in place to help decide which ones work well enough or better than others, are affordable and align with society's values to justify public funding. 
 
We believe that this tutorial will help to make cancer drug funding decisions more understandable, and will help individuals be constructive contributors in national conversations about how to best invest in new health care technologies. To that end, we ask that you share this information with your contacts by forwarding this notice. We want to ensure that as many as possible know that this tutorial is available. Your support will make a tremendous difference. 
 
If you have any questions please contact Ms. Nancy Shamanna, our SAMPS/Myeloma Canada Liason at nancysbeacon@yahoo.com.

Canadian Organization for Rare Diseases: CADTH Consultation Response